LuX-Valve Plus System for Tricuspid Regurgitation

This trial aims to determine the effectiveness and safety of the LuX-Valve Plus system, a heart valve replacement device, for treating severe tricuspid regurgitation (TR). In this condition, the heart valve doesn't close properly, causing blood to flow backward. Researchers will compare the LuX-Valve Plus system to a conventional device called EVOQUE. Participants will undergo a procedure with either the LuX-Valve Plus system or EVOQUE and attend follow-up visits. The trial seeks individuals with severe TR who experience symptoms like breathlessness or fatigue despite medication. As an unphased trial, it offers patients the chance to contribute to groundbreaking research that could enhance treatment options for TR.

Research has shown that the LuX-Valve Plus system is generally safe for patients with severe tricuspid regurgitation. Studies have found positive results with this device, achieving a high success rate of 97.6% during procedures. Most patients did not face serious complications, although about 14.3% experienced some bleeding. Additionally, 89.7% of patients survived at least one year after the procedure, highlighting the device's safety over time.

Researchers are excited about the LuX-Valve Plus system because it offers a unique approach to treating tricuspid regurgitation, a condition where the heart's tricuspid valve doesn't close tightly, leading to blood flowing backward in the heart. Traditional treatments often involve medication to manage symptoms or open-heart surgery to repair or replace the valve. Unlike these standard treatments, the LuX-Valve Plus is a minimally invasive device designed to be implanted via a catheter, which means it can be placed without the need for open-heart surgery. This new delivery method could significantly reduce recovery times and risks associated with surgery, making it an attractive option for patients who may not be suitable candidates for conventional surgical approaches. Additionally, the LuX-Valve Plus system is specifically engineered to address the unique anatomical challenges of the tricuspid valve, which could lead to better outcomes for patients.

Research has shown that the LuX-Valve Plus system effectively treats severe tricuspid regurgitation (TR), a condition where the heart valve doesn't close properly. In studies, 95.5% of patients experienced a noticeable improvement, with their TR severity reduced to a mild level. After one year, patients demonstrated better heart function and overall health. The device was successfully implanted in most cases, achieving a high success rate of 97.6% during the procedure. In this trial, participants in the randomized cohort may receive either the LuX-Valve Plus system or the EVOQUE device, while those in the single-arm cohort will receive the LuX-Valve Plus system. Overall, the LuX-Valve Plus system offers a promising treatment option for people with severe TR.²³⁴⁵⁶